Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab

被引：0
|
作者：
Cao, Z. Alexander [1 ]
Pinzon-Ortiz, Maria [1 ]
Chen, Yan [1 ]
Li, Xiaoyan [1 ]
Beltran, Pedro J. [2 ]
Gansert, Jennifer [2 ]
Peters, Malte [3 ]
Schlegel, Robert [1 ]
Schumacher, Karl M. [3 ]
Huang, Alan [1 ]
机构：
[1] Novartis, Cambridge, MA USA
[2] Amgen Inc, Thousand Oaks, CA USA
[3] Novartis, Basel, Switzerland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3683
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3683
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Analysis of PIK3CA Mutations in Breast Cancer Subtypes
    Arsenic, Ruza
    Lehmann, Annika
    Budczies, Jan
    Koch, Ines
    Prinzler, Judith
    Kleine-Tebbe, Anke
    Schewe, Christiane
    Loibl, Sibylle
    Dietel, Manfred
    Denkert, Carsten
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (01) : 50 - 56
  • [22] PIK3CA alterations in metastatic breast cancer (mBC)
    Albanell, J.
    Casadevall, D.
    Sokol, E. S.
    Albacker, L. A.
    Elvin, J. A.
    Vergilio, J-A.
    Killian, J. K.
    Ngo, N.
    Lin, D.
    Ramkissoon, S.
    Severson, E.
    Ali, S. M.
    Schrock, A. B.
    Chung, J.
    Reddy, P.
    Miller, V. A.
    Alexander, B. M.
    McGregor, K.
    Ross, J. S.
    Leyland-Jones, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 104 - +
  • [23] Characterization of PIK3CA mutations in lobular breast cancer
    Desmedt, C.
    Metzger
    Fumagalli, D.
    Brown, D.
    Singhal, S.
    Vincent, D.
    Adnet, P-Y
    Smeets, D.
    Berthed, F.
    Galant, C.
    Salgado, R.
    Veys, I.
    Saini, K.
    Pruneri, G.
    Krop, I.
    Winer, E.
    Michiels, S.
    Piccart, M.
    Lambrechts, D.
    Larsimont, D.
    Viale, G.
    Sotiriou, C.
    CANCER RESEARCH, 2012, 72
  • [24] PIK3CA H1047R Mutant Subpopulations in Normal Breast and Breast Tumors
    Myers, M. B.
    Banda, M.
    McKim, K. L.
    Wang, Y.
    Parsons, B. L.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2014, 55 : S62 - S62
  • [25] Targeting PIK3CA-mutant advanced breast cancer in the clinical setting
    Chopra, Neha
    Turner, Nicholas C.
    LANCET ONCOLOGY, 2017, 18 (07): : 842 - 843
  • [26] PIK3CA Gene Mutation Analysis in Breast Cancer Using the therascreen PIK3CA RGQ Assay in FFPE Specimen Type
    Cai, L.
    Overman, W.
    Hood, S.
    Zimmer, A.
    Wang, D.
    Kam-Morgan, L.
    Chenn, A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S65 - S65
  • [27] Mutant PIK3CA Induces EMT in a Cell Type Specific Manner
    Bhagirath, Divya
    Zhao, Xiangshan
    Mirza, Sameer
    West, William W.
    Band, Hamid
    Band, Vimla
    PLOS ONE, 2016, 11 (12):
  • [28] PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells
    Thibault, Benoit
    Thole, Adrien
    D'Angelo, Romina
    Basset, Celine
    Guillermet-Guibert, Julie
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [29] PIK3CA mutation profiling in Vietnamese patients with breast cancer
    Vuong, Linh Dieu
    Ta, To Van
    Chu, Ha Hoang
    Truong, Van-Long
    Nguyen, Quang Ngoc
    META GENE, 2020, 25
  • [30] Mutant PIK3CA Is Detected in Both Pre-Invasive and Recurrent Breast Cancer
    Kalinsky, K.
    Bhanot, U. K.
    Jacks, L. M.
    Hedvat, C. C.
    Patil, S.
    Heguy, A.
    Drobnjak, M.
    Hudis, C.
    Moynahan, M. E.
    CANCER RESEARCH, 2009, 69 (24) : 820S - 820S
12345